Because it provides a much anticipated new & innovative treatment for Relapsed/Refractory T/B-ALL patients and potentially to other CD127 expressing hematologic malignancies.

CD127 is an attractive target widely expressed across hematologic malignancies, and major solid tumors.

4A10 is clinically validated in autoimmune disorders.